Longevity Health Holdings Unaudited Q1 Sales: XAGE ~$663,000 On A Full Quarter Pro Forma Basis, Up 8% YoY; 20/20 Sales ~$562,000, Up 15% YoY

Longevity Health Holdings, Inc. (NASDAQ:XAGE), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition ("XAGE", the "Company", "we", "our", or "us"), today announced the following business updates:

1.   Merger Agreement entered with 20/20 BioLabs ("20/20")

• Merger Agreement executed on April 11, 2025, pursuant to which 20/20 is expected to continue as a wholly owned subsidiary of XAGE following merger closing subject to the satisfaction of the conditions set forth in the Merger Agreement.
• S-4 prospectus filed with the Securities and Exchange Commission (SEC) on May 8, 2025.
  
   

2.   Unaudited Q1 sales

 

• XAGE: approximately $663,000 on a full quarter pro forma basis, an increase of 8% over the same period last year.
• 20/20: approximately $562,000, an increase of 15% over the same period last year.
  
   

3.   Reverse Stock Split

 

• Completed a 1 for 30 reverse stock split of XAGE's common stock on May 12, 2025.
• Stock began trading at split adjusted price on May 14, 2025.
  
   

4.   Expected Q2 New Product Launches

 

• XAGE: expects to launch a medicated cleanser for use in Physicians' offices and MedSpas. This cleanser will also be marketed to 20/20's customer base which consists predominantly of firefighters.
• 20/20: expects to launch a new lab test that measures inflammatory biomarkers in the blood, a key contributor to premature aging and precursor to various skin and health disorders. This test will also be marketed to XAGE's customer base of physicians and MedSpas.
• 20/20: announced an initiative with Giant Food at 9 stores in Maryland and Virginia to offer OneTestTM, their multi-cancer test using capillary blood. Giant is also considering expanding the pilot to include a test that spots biomarkers linked to pro-inflammatory foods.

5.   Additional Financing

• XAGE is evaluating options and anticipates announcing a primary investment in Q2 2025.